Ernest Meinhardt
General Practice · Anchorage, AKNPI 1699768598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Novo Nordisk$372
- AstraZeneca$273
- Pfizer$209
- Merck$186
- Lilly USA, LLC$167
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,511100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $761 |
| Novo Nordisk | 23 | $372 |
| AstraZeneca(2 entities) | 17 | $273 |
| Pfizer | 9 | $209 |
| Merck | 13 | $186 |
| Lilly USA, LLC | 10 | $167 |
| GSK | 10 | $146 |
| Astellas Pharma US Inc | 6 | $140 |
| Sanofi-aventis U.S. LLC | 7 | $129 |
| Johnson & Johnson | 7 | $110 |
| Novartis | 6 | $97 |
| Myovant Sciences Inc. | 4 | $92 |
| Amarin Pharma, Inc. | 4 | $76 |
| Arbor Pharmaceuticals, Inc. | 5 | $74 |
| Abbott | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Amgen | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $55 |
| Baxter Healthcare | 1 | $47 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Exact Sciences | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $32 |
| Eisai Inc. | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$3,523 in reported general payments places this provider in the 95th percentile of 234 general practice providers in Alaska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $37,038 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,794 |
| XareltoRivaroxaban | 18 | $18,136 |
| EliquisApixaban | 20 | $18,133 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,965 |
| Nebivolol Hcl | 24 | $1,451 |
| Rosuvastatin Calcium | 52 | $877 |
| Atorvastatin Calcium | 74 | $759 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 21 | $757 |
| Olmesartan Medoxomil | 25 | $755 |
| Levothyroxine Sodium | 38 | $557 |
| Metoprolol Succinate | 36 | $528 |
| Spironolactone | 20 | $506 |
| Bisoprolol Fumarate | 17 | $491 |
| Allopurinol | 34 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet | $186 | $37,03826 claims |
| Johnson & JohnsonXarelto | $110 | $18,13618 claims |
| PfizerEliquis | $209 | $18,13320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 234 general practice providers in Alaska.
Other general practice in Anchorage
- Charles MichaelAnchorage$8K
- Evan YoungAnchorage$5K
- Franklin WorthamAnchorage$5K
- Kendall SkinnerAnchorage$5K
- Timothy LethinAnchorage$4K
- Parisa RahmanianAnchorage$2K
- Ryan WaylandAnchorage$2K
- Clinton HenrieAnchorage$2K
- Christopher CarlstonAnchorage$1K
- Mark SilvermanAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.